Compass Therapeutics (CMPX) FCF Margin (2024)
Compass Therapeutics (CMPX) posted FCF Margin of 1265.18% for Q2 2024.
Powered by 
Analysis
Compass Therapeutics (CMPX) FCF Margin (2024) Analysis & Trends
Compass Therapeutics has reported FCF Margin for 1 years, with the latest figure at 1265.18% in Q2 2024.
- Quarterly FCF Margin changed N/A year-over-year to 1265.18% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 5331.18% (down 27976.0% YoY) and the FY2024 annual result came in at 5282.24%, changed N/A from the prior year.
- FCF Margin held at 1265.18% in Q2 2024 per CMPX's latest filing.
- Over five years, FCF Margin peaked at 1265.18% in Q2 2024 and troughed at 1265.18% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Compass Therapeutics | 445.52 Mn | 445.52 Mn | - | - |